Drbengay, I believe the motive goes back to the period between the phase 3 trial failure announced in December 2011 and the time they received a delisting notice and subsequently a reverse split to remain listed, if not sooner.
The entire time BPAX sat on the discovery that restoring T-Levels in post menopausal women reduces the risk of suffering a cardiovascular event by at least 70%. In terms of cardio protective results, this is a huge number. BPAX sat on the info and let the share price suffer.
They keep working on the patent because securing a patent significantly increases the value of Libigel. Since ANI is a profitable growing company they can afford to wait until they patent prosecutions navigates the system. They do not have to dilute shareholder value as they would have under BPAX as they sought a patent.
Sentiment: Strong Buy
It sounds like there has to be a motive for ANI to put cash into completing the patent work or even expediting it. I believe the motive for purchasing Biosante was the cash they raised for phase 3, not libigel. The stockholders got tossed a bone but who knows, someone might see some value in completing the process before time tuns out. Always a surprise. Is there a market for CVR's like other rights and warrants?
J371d, the CVRs are good for a little more than 7 years and are still the responsibility of anyone who acquires Libigel or ANI. As for the patent applications, one received a Non-final rejection and it is still in play, the other patent application received a Final Rejection. Final Rejections are never really final as Request for Continued Examination (RCE) can be filed and they continue refining the breadth of the patent. If the lawyers feel they are at an impasse with the examiner, they can seek redress through the Patent Trial and Appeal Board. Presently the argued that Abbvie is deemed to have a prior art claim on one patent application and Antares Pharmaceuticals (ANI licences Libigel from Antares) has a prior art claim on the second patent application.
Unfortunately the present patent process is definitely not a lean operation.Thus the long time delays between actions.
Sentiment: Strong Buy
Is there still the possibility the CVR's will be paid from the Biosante merger? Also are the libigel studies on reducing heart disease in women still in the works? These questions are directed to Justthefactsman. You seem to have a good understanding of what may happen.
Tired of being on the wrong side of the trade? So was I until I joined PennyStock101 The alerts are quality, not junk and they are straight forward and cut out the hype.
You must have made a boat load of money on QCOR. I remember when the stock was under $1 per share. Insiders got RICH off the sale to MNK.
I owned QCOR back when they came under attack by MW, must be 3 yrs ago. The stock dropped from 38 to 20 in a few hours.
The basis for any shorting back then is that Acthar is very difficult to produce. QCOR used this as the basis for raising the price so much.
I bot more at 22, and, shame on me, was out of all those shrs at 35. Did a number of trades in it as it moved up, but when I first bot at 22, I had a baotload, and shd have just held. The negative pressure was so great, you just did not want to be holding a bigger load if there was another problem.
So I agree strongly with you, bcse I don't think MNK has the ability to drop the price too much, if ANIP gets the approvals, with similar labels, they could capture a lot of new business.
Usually analyst estimates do not include rev/earnings for drugs not yet approved, so this dev could be accretive to the 2017 eps, that would be sweet.
ANIP management is redeeming itself; look at AKRX, Endo, VRX, LRI and MNK are self destructing. I realize ANIP management/BoD member were formerly the CEOs at AKRX and Endo; however, it appears the current management are the ones that have made bad decisions. ANIP is building its business one brick at a time where the business can be rationalized one drug at a time to avoid unintended consequences from major acquisitions. The HP Acthar is a prime example where Questcor raised the price from $1400 to $28000 per vial and MNK has further raised to $32000 after it acquired Questcor for $5.7 billion. HP Acthar has many applications but like many drugs if not used properly can cause severe side effects. However, the drug still has strong revenues where ANIP can be quite aggressive with pricing considering they purchased the drug for $75 million plus royalties to Merck. ANIP will aggressively go after the HP Acthar franchise with its generic in 2017 which will be a big deal for a company with less than $100 million in revenues.
Sentiment: Strong Buy
I posted about the raised guidance a couple weks ago. If you bot the next day, at 36, you would already have a near 20% gain.
A year ago myself, and other posters here, thot 2016 was the year for ANIP, so we waited, in pain, and finally gave up.
Now it looks like 2017 will finally pan out. The most recent eps est have been raised from $3.35/sh just 7 days ago to $4.96/sh!!
At a P/E of just 10, ANIP goes to 50 in a year, but at a P/E of 15, we could see 75!!